Aktienanalyse zu Stereotaxis Inc (STXS)STXSStereotaxis Inc

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Its primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, it offers its customers x-ray systems and other accessory devices. It also provides robotic technologies for interventional cardiology and neuro-interventions. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Stereotaxis Inc. is a good buy right now due to its current price of $1.45, which is significantly lower than the average analyst price target of $3. Additionally, the company has shown a gross margin improvement to 60.31% in Q1 2026, indicating better cost management and profitability potential. The main risk is the net loss of $4.78 million reported in Q2 2026, which highlights ongoing financial challenges.

1 analysts cover STXS: 0 rate it Buy, 1 Hold and 0 Sell. The average price target is 4.20.